![[CCO] Certification Coaching Organization LLC](https://www.cco.us/wp-content/uploads/2015/05/CCO-Logo-2015-d3-500px.png "[CCO] Certification Coaching Organization LLC"){kind=logo}
🔍 Section 1: Definition
Congestive Heart Failure (CHF) is a clinical syndrome in which the heart is unable to pump sufficient blood to meet the body’s metabolic demands, or can do so only at elevated filling pressures. Per the ACC/AHA Heart Failure Guidelines, CHF encompasses a spectrum of structural and functional abnormalities causing symptoms of dyspnea, fatigue, and fluid retention.
Heart failure is classified by left ventricular ejection fraction (LVEF):
- HFrEF (Heart Failure with reduced EF): LVEF < 40% — systolic dysfunction, impaired contractility.
- HFpEF (Heart Failure with preserved EF): LVEF ≥ 50% — diastolic dysfunction, impaired relaxation and filling.
- HFmrEF (Heart Failure with mildly reduced EF): LVEF 41–49% — a transitional phenotype gaining clinical recognition.
- HFimpEF (Heart Failure with improved EF): Previously reduced EF now ≥ 40% on treatment. Per AHA Coding Clinic, code based on the current documented EF state, not the historical nadir.
Cor Pulmonale is right heart failure (RHF) caused by pulmonary hypertension from primary pulmonary disease — most commonly COPD, pulmonary fibrosis, or pulmonary arterial hypertension. Acute cor pulmonale is classically triggered by massive pulmonary embolism causing acute right ventricular pressure overload. Chronic cor pulmonale results from sustained pulmonary hypertension, leading to right ventricular hypertrophy and eventual right heart failure. See CMS FY2026 ICD-10-CM Tabular for current code assignments.
Stages of HF (ACC/AHA):
- Stage A: At risk for HF, no structural disease or symptoms
- Stage B: Structural heart disease, no HF symptoms
- Stage C: Structural disease + prior or current HF symptoms
- Stage D: Refractory/end-stage HF requiring advanced therapies (maps to I50.84)
NYHA Functional Classification (Class I–IV) documents functional limitation severity and supports CDI for acuity determination.
🗂️ Section 2: Alternative Terminology
The following table cross-maps clinical, lay, and documentation terminology to ICD-10-CM codes, enabling coders to recognize non-standard documentation that still warrants specific code assignment.
| Formal / ICD-10-CM Term | Colloquial / Lay / Clinical Synonyms | Key Coding Note |
|---|---|---|
| Systolic HF (HFrEF) | Low EF heart failure, pump failure, systolic dysfunction | Requires LVEF < 40% documentation; maps to I50.2x |
| Diastolic HF (HFpEF) | Preserved EF HF, stiff heart, diastolic dysfunction with symptoms | Requires LVEF ≥ 50% with HF symptoms; maps to I50.3x |
| Combined systolic + diastolic HF | Mixed HF, HFmrEF with both patterns | Maps to I50.4x when both explicitly documented |
| Right heart failure, isolated | Right-sided HF, RV failure, right ventricular failure | Maps to I50.81x series; distinguish from cor pulmonale |
| Biventricular failure | Both sides failing, global cardiac failure | I50.82 — requires explicit “biventricular” documentation |
| High-output HF | Hyperkinetic HF, high-output cardiac failure | I50.83 — causes include anemia, thyrotoxicosis, AV fistula |
| End-stage / Stage D HF | Refractory HF, NYHA Class IV, advanced HF | I50.84 — requires physician documentation of “end-stage” |
| HFimpEF | Recovered EF, improved ejection fraction, HF with recovered EF | Code based on current EF state per AHA Coding Clinic |
| Cor pulmonale, chronic | COPD heart failure, pulmonary heart disease, right HF from COPD | I27.81 — HCC 223; requires underlying lung disease documentation |
| Cor pulmonale, acute | Acute right heart failure from PE, acute RV overload | I26.09 or I26.01 with the pulmonary embolism code |
| Congestive heart failure | CHF, wet HF, volume overload, decompensated HF | Unspecified without further detail → I50.9; query for specificity |
| Cardiogenic pulmonary edema | Flash pulmonary edema, acute decompensated HF with pulmonary edema | J81.0 + underlying HF code; or acute HF code captures this |
| Hypertensive heart disease with HF | HTN heart failure, hypertension causing CHF | I11.0 — code first; add I50.x for HF type |
| Cardiorenal syndrome | HF with AKI, HF with CKD worsening | I13.x + I50.x + N18.x — complex sequencing rules apply |
The term “CHF” (congestive heart failure) is indexed to I50.9 (Heart failure, unspecified) in the ICD-10-CM Alphabetic Index. Always query for type (systolic/diastolic/combined) and acuity (acute/chronic/acute-on-chronic) when documentation uses only “CHF” without further specification. This single query can shift the RAF impact by over 0.1 points under HCC v28.
🩺 Section 3: Signs & Symptoms
Heart failure presents with both left-sided and right-sided congestive symptoms. Documentation of specific signs supports acuity determination and distinguishes systolic from diastolic dysfunction.
Left-Sided HF (Pulmonary Congestion)
- Dyspnea on exertion (DOE), orthopnea, paroxysmal nocturnal dyspnea (PND)
- Pulmonary edema (cardiogenic) — crackles/rales on auscultation
- S3 gallop (volume overload, systolic dysfunction) or S4 gallop (diastolic dysfunction, stiff LV)
- Decreased exercise tolerance, fatigue, weakness
- Pulsus alternans (severe systolic dysfunction)
- BNP/NT-proBNP elevation (CPT 83880)
Right-Sided HF / Cor Pulmonale (Systemic Congestion)
- Peripheral edema (bilateral pitting edema of lower extremities)
- Jugular venous distension (JVD) / elevated JVP
- Hepatomegaly, hepatojugular reflux
- Ascites, pleural effusion (often right-sided or bilateral)
- Right ventricular heave, loud P2 (pulmonary component of S2)
- Cor pulmonale: cyanosis, signs of pulmonary hypertension (e.g., RV enlargement on echo)
Diagnostic Findings
- Echocardiography: LVEF quantification (systolic vs. diastolic HF), wall motion abnormalities, RV enlargement, TR velocity for PA pressure estimation
- Chest X-ray: Cardiomegaly, Kerley B lines, cephalization, pulmonary vascular congestion, pleural effusions
- ECG: LVH pattern, LBBB (associated with systolic HF), RV strain pattern (cor pulmonale), sinus tachycardia
- Labs: BNP >100 pg/mL or NT-proBNP >300 pg/mL, elevated creatinine/BUN (cardiorenal), hyponatremia (dilutional), anemia
- Hemodynamics: Elevated PCWP (>18 mmHg left HF), elevated RAP/RVSP (right HF, cor pulmonale)
Isolated diastolic dysfunction on echo (E/A ratio, tissue Doppler) does not code as HFpEF without clinical symptoms of heart failure. Document “heart failure with preserved ejection fraction” explicitly in the assessment/plan. Diastolic dysfunction alone codes to I51.81 — which is NOT an HCC under v28.
🧭 Section 4: Differential Diagnosis
| Condition | Distinguishing Features | Key ICD-10-CM Code |
|---|---|---|
| Cardiac tamponade | Beck’s triad (hypotension, JVD, muffled heart sounds); pulsus paradoxus; Echo: pericardial effusion with RV collapse | I31.4 |
| COPD exacerbation | Obstructive pattern on PFTs, hyperinflation on CXR, bronchodilator response, low BNP; may coexist with cor pulmonale | J44.1 |
| Pulmonary embolism (PE) | Acute RV strain, D-dimer elevation, Wells score, CT-PA; acute cor pulmonale from PE → I26.0x | I26.09, I26.01 |
| Pneumonia | Fever, focal consolidation, productive cough, leukocytosis; BNP usually normal | J18.9 or organism-specific |
| Cirrhotic ascites / hepatic congestion | Liver disease history, low albumin, elevated LFTs; ascites without elevated BNP | K74.60 + R18.0 |
| Nephrotic syndrome | Massive proteinuria, hypoalbuminemia, edema; no pulmonary congestion, normal BNP | N04.x |
| Constrictive pericarditis | Pericardial calcification on imaging, equalization of diastolic pressures on cath, Kussmaul sign | I31.1 |
| Pulmonary arterial hypertension (PAH) | RHC required for diagnosis (mean PAP ≥ 25 mmHg); may cause chronic cor pulmonale | I27.0 |
| Severe anemia | High-output HF pattern; pallor, fatigue, elevated CO on echo, low hemoglobin; maps to I50.83 if HF documented | D64.9 + I50.83 |
| Acute MI with HF | Troponin elevation, ECG changes; HF as complication of MI codes under I21.x + I50.x | I21.x + I50.x |
📋 Section 5: Clinical Indicators for Coders/CDI
The following indicators prompt coders and CDI specialists to identify whether a more specific HF code is supported by clinical documentation:
| Clinical Indicator | Documentation Needed | Code Impact |
|---|---|---|
| Echocardiogram with LVEF < 40% | Provider states “systolic HF” or “HFrEF” in assessment | I50.2x vs I50.9 — HCC 221 vs no HCC |
| Echocardiogram with LVEF ≥ 50% + HF symptoms | Provider states “diastolic HF” or “HFpEF” in assessment | I50.3x vs I50.9 — HCC 221/223 |
| Acuity: acute decompensation, admission for HF | “Acute,” “acute on chronic,” or “decompensated” HF in assessment | HCC 221 (RAF ~0.331) vs HCC 223 (RAF ~0.295) |
| Hypertension + HF in same patient | Provider documents causal linkage: “HTN with HF” or “hypertensive heart disease with HF” | I11.0 + I50.x sequence required (not I10 + I50.x) |
| CKD + HF + HTN | All three conditions with causal linkage documented | I13.x + I50.x + N18.x — combination code mandatory |
| COPD/pulmonary disease + right HF | “Cor pulmonale” stated; pulmonary etiology documented | I27.81 (HCC 223) vs I50.81x (may not be HCC) |
| RV enlargement/failure from PE | “Acute cor pulmonale” stated with PE documentation | I26.01 (saddle PE w/ cor pulmonale) or I26.09 + cor pulmonale |
| End-stage HF / Stage D / NYHA IV refractory | Provider explicitly documents “end-stage,” “Stage D,” or “refractory heart failure” | I50.84 — HCC 221 (highest RAF) |
| Previously low EF now improved (HFimpEF) | Current LVEF documented ≥ 40%; physician documents current EF state | Code current EF state; if now diastolic HF, use I50.3x |
| Right HF with preserved EF (FY2024 new codes) | RHF with documented preserved ejection fraction; etiology noted | I50.A1x series — new FY2024, effective Oct 1 2023 |
When the assessment documents “CHF” without specifying type or acuity, and the chart contains an echocardiogram report with a documented LVEF, the CDI specialist should query the treating physician to (a) confirm whether the HF is systolic or diastolic based on the echo findings, and (b) clarify whether the patient’s current presentation is acute, chronic, or acute-on-chronic. This single clarification can correctly assign HCC 221 rather than HCC 223 — a difference of ~0.036 RAF points per encounter.
🦴 Section 6: Anatomy & Pathophysiology
Left Ventricular Failure
In systolic (HFrEF), cardiomyocyte loss (post-MI, dilated cardiomyopathy, myocarditis) reduces contractile force. Compensatory mechanisms — neurohormonal activation (RAAS, sympathetic), ventricular remodeling (hypertrophy, dilation) — initially maintain output but ultimately worsen dysfunction. Elevated left-sided filling pressures transmit retrograde to the pulmonary circulation, causing pulmonary venous hypertension and alveolar edema. Key references: 2022 AHA/ACC/HFSA Heart Failure Guideline.
In diastolic (HFpEF), the LV is hypertrophied and noncompliant. Impaired relaxation (lusitropy) and reduced compliance elevate diastolic filling pressures despite preserved systolic function. Common in elderly women with hypertension, obesity, and diabetes. Metabolic inflammation and microvascular dysfunction play central roles per recent pathophysiology research.
Right Ventricular Failure and Cor Pulmonale
The RV is a thin-walled, crescent-shaped chamber optimized for high-volume, low-pressure work. Unlike the LV, the RV is exquisitely sensitive to acute afterload increases. In acute cor pulmonale (typically massive PE), sudden RV pressure overload causes RV dilation, interventricular septal shift (“D-sign” on echo), decreased LV preload, and rapid hemodynamic collapse. In chronic cor pulmonale, sustained pulmonary hypertension from parenchymal lung disease (COPD, ILD) drives progressive RV hypertrophy, eventually leading to RV dilation and tricuspid regurgitation.
Neurohormonal Axis
Reduced cardiac output activates the renin-angiotensin-aldosterone system (RAAS), sympathetic nervous system, and arginine vasopressin (AVP) release. These mechanisms promote sodium and water retention (volume overload), vasoconstriction (increased afterload), and maladaptive cardiac remodeling. BNP and NT-proBNP are released in response to myocardial wall stress and serve as biomarkers of HF severity and therapeutic response.
Cardiorenal Syndrome (CRS)
In CRS Type 1 (acute HF → AKI), reduced renal perfusion from low cardiac output plus venous congestion elevates renal venous pressure and reduces GFR. In CRS Type 2 (chronic HF → CKD), chronic low output causes progressive nephron loss. When HF, HTN, and CKD coexist, combination codes I13.0 or I13.2 are required per ICD-10-CM Official Guidelines Section I.C.9.
💊 Section 7: Medication Impact / Treatment
Pharmacologic management of HF directly impacts coding and CDI by establishing diagnoses (e.g., sacubitril/valsartan use confirms HFrEF) and indicating severity (e.g., IV inotropes suggest acute/end-stage HF).
Guideline-Directed Medical Therapy (GDMT) for HFrEF
- ACE inhibitors / ARBs (e.g., lisinopril, losartan): Reduce afterload, reverse remodeling. Use in HFrEF (I50.2x).
- ARNI — Sacubitril/Valsartan (Entresto): Superior to ACE inhibitor monotherapy in HFrEF. Covered under Medicare Part D. HCPCS J3490 (unclassified) or NDC-level billing. Presence on medication list strongly implies HFrEF (systolic HF).
- Beta-blockers (carvedilol, metoprolol succinate, bisoprolol): Reduce mortality in HFrEF. May worsen acute decompensation.
- Mineralocorticoid receptor antagonists (MRA) — spironolactone, eplerenone: Reduce mortality in HFrEF; use caution with CKD and hyperkalemia.
- SGLT2 inhibitors (dapagliflozin/Farxiga, empagliflozin/Jardiance): Now Class I indication for both HFrEF and HFpEF per 2022 guideline update. Covered under Part D.
- Vericiguat (Verquvo): sGC stimulator for high-risk HFrEF. Part D coverage. HCPCS unclassified (J3490 or equivalent).
- Diuretics (furosemide, bumetanide, torsemide): Symptomatic relief of congestion. IV diuresis supports acute/decompensated HF coding.
- Hydralazine/nitrates: Alternative to RAAS blockade; particularly in Black patients with HFrEF or when ACE/ARB contraindicated.
- Ivabradine (Corlanor): HR reduction for HFrEF with sinus tachycardia on max-dose beta-blocker.
- Digoxin: Older agent for symptom control in HFrEF with atrial fibrillation.
Acute / Inpatient HF Management (HCPCS-Billable Infusions)
- Dobutamine (J1250): Positive inotrope for acute decompensated HFrEF; IV infusion. Supports acute HF diagnosis.
- Milrinone (J1952): PDE-3 inhibitor inotrope/vasodilator for acute HF or bridge to transplant/LVAD.
- Dopamine (J1265): Low-dose for renal perfusion; higher dose for cardiogenic shock.
- Heparin (J1644): Anticoagulation in HF with AF, DVT/PE, or device-related thrombosis.
- IV loop diuretics: Furosemide (J1940), bumetanide (J0395) for acute volume overload.
- Nesiritide (Natrecor): BNP analog vasodilator; J2325.
Device and Advanced Therapies
- ICD (Implantable Cardioverter-Defibrillator): Primary prevention in HFrEF with LVEF ≤ 35%. HCPCS C1721, C1722 for device components.
- CRT-D (Cardiac Resynchronization Therapy with ICD): For HFrEF with LBBB; improves LVEF (may create HFimpEF). HCPCS C9604.
- LVAD / VAD: Bridge to transplant or destination therapy for end-stage HF. CPT 33975–33983; HCPCS Q0478 (VAD component).
- ECMO: Temporary circulatory support in cardiogenic shock. CPT 33960–33966.
- Impella: Percutaneous ventricular assist device. CPT 33990–33993.
- Heart Transplant: Definitive therapy for refractory HF; postoperative status Z94.1.
Cor Pulmonale Treatment
Treatment targets the underlying pulmonary disease: bronchodilators and inhaled corticosteroids for COPD-related cor pulmonale; anticoagulation and embolectomy/thrombolytics for PE-associated acute cor pulmonale; pulmonary vasodilators (sildenafil, riociguat, prostacyclins) for PAH-related cor pulmonale.
Preview ends here. The full guide continues with FY2026 ICD-10-CM code sets, CPT surgical coding, HCC v28 risk adjustment mapping, CDI query templates, and an audit checklist — all available to CCO Members.
← Back to All Clinical Documentation Guides
📘 Section 8: ICD-10-CM Guidelines (FY2026)
Heart failure coding is governed by ICD-10-CM Official Guidelines for Coding and Reporting, Section I.C.9 (Diseases of the Circulatory System). Key rules for FY2026:
Guideline I.C.9.a — Hypertension with Heart Disease
A causal relationship between hypertension and heart failure is assumed when both are documented in the same record (unless the physician specifies a different cause). Therefore, when a patient has hypertension and heart failure:
- Assign I11.0 (Hypertensive heart disease with heart failure) as the principal/first-listed code — NOT I10 (HTN alone) + I50.x separately.
- Use an additional code from I50.x to specify the type of heart failure (e.g., I50.22 for chronic systolic HF).
- If hypertension, heart disease, AND CKD are all present: use I13.0 (with stage 1–4 or unspecified CKD) or I13.2 (with stage 5 or ESRD), plus additional codes I50.x and N18.x.
Common audit finding: Coders assign I10 (Essential hypertension) + I50.9 (CHF unspecified) as two separate codes when both conditions are documented. Per ICD-10-CM Guideline I.C.9.a, the correct code is I11.0 (hypertensive heart disease with HF) as the combination code, plus the specific I50.x HF type. Failure to use I11.0 is a Top 10 OIG audit target for inpatient HF claims.
Guideline I.C.9.b — Hypertension with Heart Disease and CKD (I13.x)
When all three conditions (hypertension + heart disease + CKD) are present:
- I13.0: Hypertensive heart and CKD with HF and CKD stages 1–4 or unspecified CKD. Use additional codes: I50.x (HF type) + N18.1–N18.4 or N18.9 (CKD stage).
- I13.10: Hypertensive heart and CKD without HF, with CKD stages 1–4 or unspecified.
- I13.2: Hypertensive heart and CKD with HF and CKD stage 5 or ESRD. Use additional I50.x + N18.5/N18.6 + Z99.2 if on dialysis.
- Sequencing: I13.x is always listed first; I50.x and N18.x follow as additional codes. Never sequence I50.x before I13.x when the combination condition exists.
Guideline I.C.9.e — Acute Myocardial Infarction (AMI) with Subsequent HF
Heart failure arising after MI within the 4-week acute period codes with I21.x (AMI) as principal, with I50.x as secondary for HF as a complication. After 4 weeks, I22.x (subsequent MI) or late effects codes may apply.
Acute, Chronic, and Acute-on-Chronic HF
Per ICD-10-CM conventions and AHA Coding Clinic guidance, when both acute and chronic HF are documented for the same type:
- Only one code is needed: the acute-on-chronic combination code (e.g., I50.23 for acute-on-chronic systolic HF).
- Do not code both I50.21 (acute systolic) and I50.22 (chronic systolic) separately — use I50.23.
- The acute-on-chronic designation carries higher HCC weight (HCC 221, RAF ~0.331) versus chronic alone (HCC 223, RAF ~0.295).
Cor Pulmonale Coding Principles
- Chronic cor pulmonale (I27.81): Assign when right heart failure is secondary to pulmonary hypertension caused by primary pulmonary disease (COPD, ILD, PAH). Code the underlying pulmonary condition additionally.
- Acute cor pulmonale with PE (I26.01 or I26.09): Acute cor pulmonale is classified within the pulmonary embolism codes (I26.x). I26.01 = saddle embolus with acute cor pulmonale; I26.09 = other PE with acute cor pulmonale.
- Do not confuse chronic cor pulmonale (I27.81) with isolated right HF (I50.81x). Cor pulmonale requires pulmonary hypertension from pulmonary disease as the etiology.
FY2024 New Codes (Effective October 1, 2023; Active FY2026)
The following right HF codes with preserved/reduced EF were introduced in FY2024 and remain active in FY2026 per CMS FY2024 ICD-10-CM Update:
- I50.A1, I50.A11, I50.A19: Right heart failure with preserved ejection fraction (right HFpEF)
- I50.A2x: Right heart failure with reduced ejection fraction (right HFrEF)
- These codes require documentation of both the right-sided HF AND the preserved or reduced EF status.
HFimpEF (Improved EF)
Per AHA Coding Clinic (see Section 13), when a patient previously had HFrEF but current LVEF has improved to ≥ 40% (or ≥ 50%), code based on the current documented EF state. If currently ≥ 50% with HF symptoms → I50.3x (diastolic/HFpEF). Always document the current LVEF to support the most appropriate code.
Rheumatic Heart Failure
I09.81 (Rheumatic heart failure) applies when rheumatic fever or rheumatic heart disease is the documented cause of HF. This is a separate etiology from hypertensive or ischemic HF. Do not use I50.x when rheumatic heart disease is the documented cause — I09.81 is the correct code.
Codes that do NOT map to HCC under v28: I51.4 (Myocarditis, unspecified), I51.5 (Myocardial degeneration), I51.7 (Cardiomegaly), I51.81 (Takotsubo syndrome / diastolic dysfunction alone), and I51.89 (Other ill-defined heart diseases) are not assigned to HCC 221 or 223 under CMS-HCC v28. These are commonly confused with HF codes but lack HCC-qualifying specificity. Always obtain clarification if only these codes appear in the HF patient’s chart.
🔢 Section 9: ICD-10-CM Code Set (FY2026)
Heart Failure (I50.x) — Full Matrix
| ICD-10-CM Code | Description | HCC v28 | Notes |
|---|---|---|---|
| I50.1 | Left ventricular failure, unspecified | HCC 223 | Includes cardiac asthma; query for acuity |
| I50.20 | Unspecified systolic (congestive) heart failure | HCC 223 | Query for acuity (acute/chronic/AoC) |
| I50.21 | Acute systolic (congestive) heart failure | HCC 221 | Acute HF; highest RAF in category |
| I50.22 | Chronic systolic (congestive) heart failure | HCC 223 | Stable, managed systolic HF |
| I50.23 | Acute on chronic systolic (congestive) heart failure | HCC 221 | Most common inpatient admission code; RAF ~0.331 |
| I50.30 | Unspecified diastolic (congestive) heart failure | HCC 223 | HFpEF unspecified acuity |
| I50.31 | Acute diastolic (congestive) heart failure | HCC 221 | Acute HFpEF; flash pulmonary edema common presentation |
| I50.32 | Chronic diastolic (congestive) heart failure | HCC 223 | Stable HFpEF, outpatient management |
| I50.33 | Acute on chronic diastolic (congestive) heart failure | HCC 221 | Decompensated HFpEF; RAF ~0.331 |
| I50.40 | Unspecified combined systolic and diastolic heart failure | HCC 223 | Both systolic + diastolic documented, acuity unspecified |
| I50.41 | Acute combined systolic and diastolic HF | HCC 221 | Acute mixed presentation |
| I50.42 | Chronic combined systolic and diastolic HF | HCC 223 | Stable combined HF |
| I50.43 | Acute on chronic combined systolic and diastolic HF | HCC 221 | RAF ~0.331 |
| I50.810 | Right heart failure, unspecified | HCC 223 | Distinguish from cor pulmonale (I27.81) |
| I50.811 | Acute right heart failure | HCC 221 | Acute RHF not due to left HF or PE |
| I50.812 | Chronic right heart failure | HCC 223 | Stable RHF |
| I50.813 | Acute on chronic right heart failure | HCC 221 | Decompensated RHF; RAF ~0.331 |
| I50.814 | Right heart failure due to left heart failure | HCC 223 | Biventricular with left cause; do not also code I50.82 |
| I50.82 | Biventricular heart failure | HCC 223 | Requires explicit “biventricular” documentation |
| I50.83 | High output heart failure | HCC 223 | Anemia, thyrotoxicosis, AV fistula; high CO with HF symptoms |
| I50.84 | End-stage heart failure | HCC 221 | Stage D; LVAD candidate, transplant candidate, or comfort care |
| I50.89 | Other heart failure | HCC 223 | Not elsewhere classified |
| I50.9 | Heart failure, unspecified | HCC 223 | “CHF” without type/acuity; always query for specificity |
| I50.A1 | Right heart failure with preserved ejection fraction, unspecified | HCC 223 | New FY2024; right HFpEF unspecified acuity |
| I50.A11 | Acute right heart failure with preserved ejection fraction | HCC 221 | New FY2024; acute right HFpEF |
| I50.A19 | Chronic right heart failure with preserved ejection fraction | HCC 223 | New FY2024; chronic right HFpEF |
| I50.A21 | Acute right heart failure with reduced ejection fraction | HCC 221 | New FY2024; acute right HFrEF |
| I50.A29 | Chronic right heart failure with reduced ejection fraction | HCC 223 | New FY2024; chronic right HFrEF |
Cor Pulmonale and Related Codes
| ICD-10-CM Code | Description | HCC v28 | Notes |
|---|---|---|---|
| I26.01 | Saddle embolus of pulmonary artery with acute cor pulmonale | HCC 221 | Massive PE; high mortality risk |
| I26.09 | Other pulmonary embolism with acute cor pulmonale | HCC 221 | Non-saddle PE with acute RV overload |
| I26.02 | Saddle embolus without acute cor pulmonale | — | Saddle PE without RV failure |
| I26.90 | Pulmonary embolism, unspecified, without acute cor pulmonale | — | Query for cor pulmonale if RV dysfunction documented |
| I27.0 | Primary pulmonary hypertension | HCC 158 | Idiopathic PAH; causes chronic cor pulmonale |
| I27.81 | Cor pulmonale (chronic) | HCC 223 | RHF from pulmonary disease; code underlying condition additionally |
| I27.82 | Chronic pulmonary embolism | HCC 223 | CTEPH; may cause chronic cor pulmonale; code I27.81 additionally if cor pulmonale present |
| I27.9 | Pulmonary heart disease, unspecified | — | Not HCC; query for specific pulmonary heart disease diagnosis |
Hypertensive Heart Failure Combination Codes
| ICD-10-CM Code | Description | Use Additional Code | Notes |
|---|---|---|---|
| I11.0 | Hypertensive heart disease with heart failure | I50.x (HF type) | Code first when HTN + HF; assumed causal relationship |
| I13.0 | Hypertensive heart and CKD with HF, CKD stage 1–4 or unspecified | I50.x + N18.1–N18.4 or N18.9 | All three conditions present |
| I13.2 | Hypertensive heart and CKD with HF, CKD stage 5 or ESRD | I50.x + N18.5 or N18.6 + Z99.2 if dialysis | Add Z99.2 if on dialysis |
| I09.81 | Rheumatic heart failure | — | Rheumatic disease as etiology of HF; not I50.x |
When a patient has hypertension, heart failure, AND CKD, coders must use I13.0 or I13.2 (not I11.0 + N18.x separately). Failure to use the I13.x combination code is a common DRG validation audit finding. Always verify all three conditions are documented and that HF is the current encounter reason before applying I13.x.
🔎 Section 10: Indexing
The following alphabetic index pathways guide correct code lookup in the ICD-10-CM Alphabetic Index:
| Index Entry | Subterms / Qualifiers | Code(s) |
|---|---|---|
| Failure, heart | (congestive) | I50.9 |
| Failure, heart | systolic → see Failure, ventricular, left, systolic | I50.20–I50.23 |
| Failure, heart | diastolic → see Failure, ventricular, left, diastolic | I50.30–I50.33 |
| Failure, heart | combined systolic and diastolic | I50.40–I50.43 |
| Failure, heart | right (secondary to left) → see Failure, heart, right | I50.810–I50.814 |
| Failure, heart | biventricular | I50.82 |
| Failure, heart | high output | I50.83 |
| Failure, heart | end stage | I50.84 |
| Cor pulmonale | (chronic) | I27.81 |
| Cor pulmonale | acute → see Embolism, pulmonary, with cor pulmonale | I26.01 or I26.09 |
| Disease, heart, hypertensive | with heart failure | I11.0 |
| Disease, heart, hypertensive | with CKD and HF → see Hypertension, heart and CKD | I13.0, I13.2 |
| CHF | (see also Failure, heart, congestive) | I50.9 |
| Cardiomegaly | — | I51.7 (NOT HCC) |
| Diastolic dysfunction | alone (no HF symptoms) | I51.81 (NOT HCC) |
| Failure, ventricular, right | acute on chronic | I50.813 |
“Congestive heart failure” indexed directly goes to I50.9. The coder must apply the full subterm pathway for systolic (I50.2x), diastolic (I50.3x), combined (I50.4x), or right HF (I50.81x) — these are NOT default index entries for “CHF.” Always review the complete visit documentation, including echocardiogram reports, and apply the most specific code supported by physician documentation.
🏥 Section 11: CPT (2026)
The following CPT codes are relevant to the diagnosis, monitoring, and management of heart failure and cor pulmonale per the AMA CPT 2026 Manual:
| CPT Code | Description | Global | Clinical Notes |
|---|---|---|---|
| 83880 | Natriuretic peptide (BNP or NT-proBNP) | N/A (lab) | Quantitative serum biomarker; key HF diagnosis/monitoring test |
| 93306 | Echocardiography, TTE with Doppler (complete) | N/A | Primary test for LVEF, wall motion, valvular disease; establishes HF type |
| 93350 | Stress echocardiography (treadmill or bicycle) | N/A | Ischemic etiology of HF; diastolic stress echo for HFpEF evaluation |
| 93351 | Stress echo with Doppler and/or color flow | N/A | Enhanced stress echo with hemodynamic assessment |
| 93355 | Transesophageal echo (TEE) with 3D reconstruction | N/A | Valvular HF (MR, AR), pre-operative device assessment |
| 93458 | Left heart catheterization | 000 | LVEF, PCWP, coronary artery evaluation in HF |
| 93459 | Left heart cath with left ventriculography | 000 | Includes LV function assessment |
| 93460 | Right and left heart catheterization | 000 | Full hemodynamic assessment; PAP, PCWP, CO for HF staging |
| 93461 | Right and left heart cath with imaging | 000 | Comprehensive hemodynamic + angiographic |
| 92920 | Percutaneous transluminal coronary angioplasty (PTCA), single vessel | 090 | PCI for ischemic HFrEF revascularization |
| 92928 | PCI with stent, single vessel | 090 | Drug-eluting stent; ischemic HF revascularization |
| 92944 | PCI, chronic total occlusion | 090 | CTO PCI for ischemic cardiomyopathy |
| 33975 | LVAD insertion (extracorporeal) | 090 | Bridge to transplant or destination therapy in end-stage HF |
| 33976 | LVAD insertion (intracorporeal) | 090 | Implantable LVAD (e.g., HeartMate 3, HVAD) |
| 33977 | LVAD removal | 090 | Post-transplant or recovery |
| 33983 | LVAD replacement of pump | 090 | Device exchange |
| 33990 | Insertion of Impella (percutaneous LV assist device) | 000 | Cardiogenic shock, high-risk PCI support |
| 33991 | Insertion of Impella with open cardiac procedure | 000 | Surgical Impella placement |
| 33992 | Removal of Impella catheter | 000 | Separate procedure |
| 33993 | Repositioning of Impella catheter | 000 | Image-guided repositioning |
| 33960 | ECMO insertion, arteriovenous (VA-ECMO) | 090 | Cardiogenic shock, cardiac arrest; temporary support |
| 33966 | ECMO insertion, venovenous (VV-ECMO) | 090 | Respiratory failure with RHF, cor pulmonale |
| 93793 | Anticoagulation management (in-office, per 90 days) | N/A | HF patients on warfarin for AF, mechanical valves, or device thrombosis |
| 99495 | Transitional Care Management (TCM), 14-day discharge contact | N/A | HF readmission reduction; moderate MDM |
| 99496 | TCM, 7-day discharge contact, high medical decision complexity | N/A | High-complexity HF patients; face-to-face within 7 days |
NT-proBNP vs BNP: Both are reported with CPT 83880 (Natriuretic peptide). NT-proBNP is the more commonly ordered test and has different reference ranges than BNP. The CPT code is the same for both. Documenting which peptide was ordered and the result value supports medical necessity for HF diagnosis confirmation.
🧾 Section 12: HCPCS (2026)
| HCPCS Code | Description | Typical Use / Notes |
|---|---|---|
| J1250 | Injection, dobutamine HCl, per 250 mg | Acute decompensated HFrEF; inotropic support; IV infusion in hospital/outpatient |
| J1265 | Injection, dopamine HCl, 40 mg | Cardiogenic shock, low-output HF; renal dose dopamine (low dose) |
| J1952 | Injection, milrinone lactate, 5 mg | PDE-3 inhibitor for acute HF, bridge therapy; IV infusion |
| J1644 | Injection, heparin sodium, per 1000 USP units | HF with AF, DVT/PE prophylaxis, LVAD/device thrombosis prevention |
| C9604 | CRT-D device (cardiac resynchronization therapy with defibrillator) | HFrEF with LBBB, LVEF ≤ 35%; biventricular pacing + ICD; per implant |
| C1721 | Cardioverter-defibrillator, dual chamber (implantable) | ICD for HFrEF primary prevention (LVEF ≤ 35%) |
| C1722 | Cardioverter-defibrillator, single chamber (implantable) | Single-chamber ICD; appropriate for many HFrEF patients |
| Q0478 | VAD component (non-pump) | LVAD system components (controllers, accessories) billed separately from implant |
| J3490 | Unclassified drug (sacubitril/valsartan, vericiguat when no specific J-code) | Entresto (sacubitril/valsartan) — HFrEF GDMT; Medicare Part D (oral); use J3490 for infusion formulations only. Vericiguat (Verquvo) similarly billed under J3490 or Part D NDC. |
| J2325 | Injection, nesiritide, 0.1 mg | Natrecor (BNP analog vasodilator) for acute decompensated HF |
| J1940 | Injection, furosemide, 20 mg | IV loop diuretic for acute HF/decompensation; most commonly billed HF drug |
| J0395 | Injection, arbutamine HCl — note: bumetanide billed separately | IV diuresis for acute HF |
Part D vs Medical Benefit: Sacubitril/valsartan (Entresto) and vericiguat (Verquvo) are oral medications covered under Medicare Part D, not the Part B medical benefit. They are not billed with HCPCS J-codes in the outpatient Part B setting. HCPCS J3490 applies only when a drug lacks its own J-code and is administered in a provider office or infusion center setting. For these oral HF agents, ensure the Part D formulary coverage status is verified for Medicare patients. Pegloticase (J2503) and ceftazidime (J0714) are not applicable to HF care.
📚 Section 13: AHA Coding Clinic (Recent Guidance)
| Reference | Topic | Guidance Summary |
|---|---|---|
| AHA Coding Clinic, 4Q 2023 | HFimpEF — Heart Failure with Improved EF | Code based on the current documented EF state. If the patient had HFrEF but now has LVEF ≥ 40%, code the current EF classification. Do not code the historical reduced EF if the current EF is improved/preserved. Physician must document current EF. |
| AHA Coding Clinic, 3Q 2023 | Right HF New Codes (FY2024) | I50.A1x (right HFpEF) and I50.A2x (right HFrEF) codes became effective Oct 1, 2023 (FY2024). These require documentation of both the right-sided HF and preserved or reduced EF. Query the physician when right HF is documented and echo shows EF. |
| AHA Coding Clinic, 2Q 2022 | HTN + HF Causal Assumption | Reaffirmed: causal relationship between HTN and HF is assumed per guideline I.C.9.a. Always assign I11.0 when both are documented unless physician explicitly documents a different cause for HF. Do not separately code I10 + I50.x when I11.0 applies. |
| AHA Coding Clinic, 1Q 2021 | Acute cor pulmonale with PE | Acute cor pulmonale associated with PE is classified within the I26.x codes (I26.01 saddle PE with cor pulmonale; I26.09 other PE with cor pulmonale). Do not additionally assign I27.81 (chronic cor pulmonale) for acute presentations unless chronic cor pulmonale is also separately documented and present. |
| AHA Coding Clinic, 4Q 2020 | End-stage HF (I50.84) | Code I50.84 requires explicit physician documentation of “end-stage” heart failure. NYHA Class IV or Stage D HF alone is not sufficient unless the physician explicitly documents “end-stage.” Query when clinical indicators (LVAD, transplant listing, hospice) suggest end-stage but documentation is absent. |
| AHA Coding Clinic, 2Q 2019 | Diastolic dysfunction without HF symptoms | Isolated diastolic dysfunction (I51.81) is NOT the same as diastolic HF (I50.3x). Diastolic dysfunction requires clinical symptoms of heart failure (dyspnea, edema, fatigue) to qualify as HFpEF. Code I51.81 only when diastolic dysfunction is documented without HF symptoms. I51.81 is not an HCC. |
| AHA Coding Clinic, 1Q 2018 | I13.x Sequencing Rules | When I13.0 or I13.2 is used (HTN + HF + CKD), the I13.x code is always first-listed. Additional codes I50.x and N18.x are required — not optional. This is a mandatory “use additional code” instruction in the tabular. |
💰 Section 14: HCC / Risk Adjustment (v28)
Under CMS-HCC Model v28 (effective payment year 2024, fully phased in by 2026), heart failure codes map to two primary HCCs:
- HCC 221 — Acute Heart Failure: RAF weight approximately 0.331. Applies to acute, acute-on-chronic, and end-stage HF codes.
- HCC 223 — Chronic Heart Failure, Cor Pulmonale, and HF NOS: RAF weight approximately 0.295. Applies to chronic, unspecified HF codes, and cor pulmonale.
Key principle: HCC 221 (acute) outweighs HCC 223 (chronic) by ~0.036 RAF points. For a Medicare Advantage plan with a benchmark of $800/member/month, this translates to a significant payment difference when extrapolated across a population. Accurate documentation and coding of acuity is therefore both a clinical accuracy imperative and a revenue integrity issue.
| ICD-10-CM Code | Description | HCC v28 | RAF Weight (approx.) | Coding Notes |
|---|---|---|---|---|
| I50.21 | Acute systolic HF | HCC 221 | ~0.331 | Single acute episode |
| I50.23 | Acute on chronic systolic HF | HCC 221 | ~0.331 | Most common inpatient HFrEF code |
| I50.31 | Acute diastolic HF | HCC 221 | ~0.331 | Flash pulmonary edema, HFpEF decompensation |
| I50.33 | Acute on chronic diastolic HF | HCC 221 | ~0.331 | Decompensated HFpEF |
| I50.41 | Acute combined systolic+diastolic HF | HCC 221 | ~0.331 | — |
| I50.43 | Acute on chronic combined HF | HCC 221 | ~0.331 | — |
| I50.811 | Acute right HF | HCC 221 | ~0.331 | — |
| I50.813 | Acute on chronic right HF | HCC 221 | ~0.331 | — |
| I50.84 | End-stage HF | HCC 221 | ~0.331 | Stage D; highest clinical severity |
| I50.A11 | Acute right HFpEF | HCC 221 | ~0.331 | New FY2024 code |
| I50.A21 | Acute right HFrEF | HCC 221 | ~0.331 | New FY2024 code |
| I50.22 | Chronic systolic HF | HCC 223 | ~0.295 | Stable HFrEF outpatient |
| I50.32 | Chronic diastolic HF | HCC 223 | ~0.295 | Stable HFpEF outpatient |
| I50.9 | HF unspecified | HCC 223 | ~0.295 | Always query for specificity |
| I27.81 | Chronic cor pulmonale | HCC 223 | ~0.295 | Right HF from pulmonary disease |
| I27.82 | Chronic pulmonary embolism | HCC 223 | ~0.295 | CTEPH; may have cor pulmonale |
| I51.4 | Myocarditis, unspecified | NOT HCC | — | Do not confuse with HF codes |
| I51.5 | Myocardial degeneration | NOT HCC | — | Not an HCC in v28 |
| I51.7 | Cardiomegaly | NOT HCC | — | Not an HCC in v28 |
| I51.81 | Takotsubo / diastolic dysfunction alone | NOT HCC | — | Without HF symptoms; not HCC |
| I51.89 | Other ill-defined heart diseases | NOT HCC | — | Not an HCC in v28 |
HCC v28 Phase-In: CMS is phasing in the v28 model (blending v24 and v28 for payment years 2024–2026). For payment year 2026, the model is fully transitioned to v28. Coders and CDI specialists should use v28 HCC assignments exclusively for FY2026 encounters. The reclassification of several HF codes between v24 and v28 affects risk score calculations for Medicare Advantage plans and ACO participants. Verify your risk adjustment software has been updated to v28 mappings.
✍️ Section 15: CDI Query Templates
All queries below follow AHIMA/ACDIS compliant query standards: non-leading, multiple-choice format with a clinical indicator summary and “other/unable to determine” options.
| Query Scenario | Clinical Trigger | Query Template (Abbreviated) |
|---|---|---|
| HF Type Unspecified — Systolic vs. Diastolic | Documentation states “CHF” or “heart failure” without type; echocardiogram in chart | “Based on the clinical documentation, echocardiography findings (LVEF ___%), and clinical presentation, can you clarify the type of heart failure? Options: (a) Systolic heart failure/HFrEF (LVEF <40%), (b) Diastolic heart failure/HFpEF (LVEF ≥50%), (c) Combined systolic and diastolic HF, (d) Other: ___, (e) Unable to determine.” |
| Acuity Not Documented — Acute vs. Chronic | HF documented but no designation of acute, chronic, or acute-on-chronic; patient admitted for HF decompensation | “The patient was admitted with heart failure requiring IV diuresis. Can you clarify the acuity of the heart failure? Options: (a) Acute heart failure (new onset/single episode), (b) Chronic heart failure (stable, ongoing), (c) Acute on chronic heart failure (known chronic HF with acute decompensation), (d) Other: ___, (e) Unable to determine.” |
| HFpEF vs HFrEF from EF Documentation | Echo LVEF value present in chart but physician’s assessment does not specify HF type | “The echocardiogram dated [date] documents an LVEF of ___%. The patient carries a diagnosis of heart failure. Based on the documented EF and clinical findings, can you specify: (a) HFrEF (systolic HF, LVEF <40%), (b) HFpEF (diastolic HF, LVEF ≥50%), (c) HFmrEF (mildly reduced EF, LVEF 41-49%), (d) Other: ___, (e) Unable to determine.” |
| Hypertension + Heart Failure — Causal Linkage | Patient has both hypertension (on antihypertensives) and heart failure documented, coded separately as I10 + I50.x | “The patient has documented diagnoses of both hypertension and heart failure. Is the heart failure causally related to the hypertension (i.e., hypertensive heart disease with heart failure)? Options: (a) Yes — hypertensive heart disease with heart failure (I11.0), (b) No — heart failure is due to another etiology: ___, (c) Unable to determine.” |
| Heart Failure + CKD + HTN — I13.x Sequencing | All three conditions documented; coded separately or only I11.0 used without N18.x | “The patient has documented hypertension, heart failure, and CKD. Are all three conditions present and causally related? If so, please confirm: (a) The CKD stage (N18.1–N18.5/N18.6), (b) Whether dialysis is present (Z99.2), and (c) Confirm hypertensive heart and chronic kidney disease with heart failure for combination code I13.0 or I13.2. Or (d) Other etiology for HF: ___, (e) Unable to determine.” |
| Cor Pulmonale Etiology | Right heart failure or RV enlargement documented; pulmonary disease also present (COPD, ILD, PAH) | “The patient has right-sided heart failure with documented pulmonary disease ([COPD/ILD/PAH]). Is the right heart failure secondary to pulmonary hypertension from the pulmonary disease (cor pulmonale)? Options: (a) Yes — chronic cor pulmonale (I27.81) due to [COPD/ILD/other], (b) Right HF secondary to left heart failure (I50.814), (c) Right HF, other etiology: ___, (d) Unable to determine.” |
| End-Stage / Stage D Documentation | Patient has LVAD, on transplant list, in cardiac hospice, or has NYHA Class IV refractory symptoms | “Clinical indicators (e.g., LVAD implant, transplant candidacy evaluation, NYHA Class IV refractory to maximal GDMT) suggest advanced heart failure. Can you document whether this patient has end-stage (Stage D) heart failure? Options: (a) Yes — end-stage heart failure (I50.84), (b) Advanced HF but not end-stage at this time, (c) Other: ___, (d) Unable to determine.” |
| Right HFpEF vs Right HFrEF (New FY2024 Codes) | Right-sided HF documented; echo includes RV and LV EF data; FY2024+ encounter | “The patient has documented right heart failure. The echocardiogram shows [preserved/reduced] ejection fraction. Can you confirm: (a) Right heart failure with preserved EF (I50.A1x), (b) Right heart failure with reduced EF (I50.A2x), (c) Right HF, EF status not determinable, (d) Other: ___, (e) Unable to determine.” |
High-yield HF query opportunity: Any inpatient encounter with a principal diagnosis of I50.9 (HF unspecified) should trigger a concurrent CDI query for both type and acuity. A successful query converting I50.9 to I50.23 (acute-on-chronic systolic HF) not only improves HCC capture (HCC 221 vs 223) but may also affect the MS-DRG assignment — DRG 291 (HF w/ MCC) vs DRG 292 (HF w/ CC) vs DRG 293 (HF without CC/MCC). The difference in geometric mean LOS and expected payment between DRG 291 and 293 can exceed $3,000 per case.
🧑⚕️ Section 16: Treatments (Clinical)
Acute Decompensated HF (ADHF) Management
Per 2022 AHA/ACC/HFSA Heart Failure Guidelines:
- Diuresis: IV loop diuretics (furosemide, bumetanide, torsemide) for volume overload. DOSE trial evidence supports higher-dose diuresis for decongestion. Monitor renal function, electrolytes.
- Vasodilators: IV nitroglycerin or nesiritide for afterload reduction in acute HFrEF or acute cardiogenic pulmonary edema with hypertension.
- Inotropes: Dobutamine or milrinone for cardiogenic shock or low-output state. Reserved for hemodynamically compromised patients (systolic BP <90 mmHg, low CO).
- Oxygen/Ventilatory Support: Non-invasive positive pressure ventilation (CPAP/BiPAP) for cardiogenic pulmonary edema; intubation for refractory hypoxia.
- Mechanical Circulatory Support (MCS): Impella (CPT 33990–33993) or IABP for cardiogenic shock bridging. VA-ECMO (CPT 33960) for refractory shock.
Chronic Stable HF Management (GDMT)
- HFrEF (LVEF < 40%): Four-pillar GDMT — ARNI/ACEi/ARB + beta-blocker + MRA + SGLT2 inhibitor. Target doses per guidelines. Avoid NSAIDs, non-dihydropyridine CCBs, most antiarrhythmics.
- HFpEF (LVEF ≥ 50%): SGLT2 inhibitors (Class IIa recommendation per 2022 guidelines), diuretics for congestion, treat underlying comorbidities (HTN, AF, obesity, DM). Limited mortality-benefit drugs specific to HFpEF.
- Device Therapy: ICD for primary prevention (LVEF ≤ 35%, NYHA II–III, on GDMT ≥ 3 months). CRT-D for LVEF ≤ 35% with LBBB (QRS ≥ 150 ms). Wearable defibrillator (LifeVest) as bridge after new HFrEF diagnosis.
- Cardiac Rehabilitation: Class I recommendation for stable ambulatory HF patients. Improves functional capacity and quality of life.
- Sodium Restriction: <2–3 g/day. Fluid restriction (<1.5–2 L/day) for dilutional hyponatremia or advanced HF.
Advanced HF (Stage D) Therapies
- LVAD (Destination Therapy or BTT): HeartMate 3 demonstrated superiority in MOMENTUM 3 trial. Continuous-flow devices; requires lifelong anticoagulation, battery management, driveline exit site care.
- Heart Transplantation: Gold standard for end-stage HF; limited by donor availability. Requires immunosuppression. Post-transplant status: Z94.1.
- Palliative Care / Hospice: Appropriate for end-stage HF patients declining advanced therapies. Symptom management focus.
Cor Pulmonale (Chronic) Treatment
- Treat the Underlying Pulmonary Disease: COPD — bronchodilators, inhaled steroids, smoking cessation, pulmonary rehabilitation, supplemental oxygen (improves pulmonary hypertension and RV function).
- Long-term Oxygen Therapy (LTOT): Reduces pulmonary vascular resistance, improves exercise tolerance, and slows progression of cor pulmonale in hypoxic COPD patients.
- Pulmonary Vasodilators: For PAH-related cor pulmonale — sildenafil (PDE-5 inhibitor), riociguat (sGC stimulator), prostacyclin analogs (epoprostenol, treprostinil), endothelin receptor antagonists (bosentan). Not routinely used for COPD-related cor pulmonale (may worsen V/Q mismatch).
- Diuretics: For right-sided congestion (JVD, ascites, peripheral edema). Avoid over-diuresis in RHF (reduces RV preload and may worsen low CO).
- Anticoagulation: For CTEPH (I27.82) — lifelong anticoagulation; pulmonary endarterectomy (PEA) for operable CTEPH; riociguat or balloon pulmonary angioplasty for inoperable CTEPH.
🎓 Section 17: Patient Education / Summary
Summary for Healthcare Professionals
Heart failure is a major chronic disease affecting approximately 6.7 million Americans with an annual direct cost exceeding $30 billion. Optimal ICD-10-CM coding requires capturing three dimensions of specificity: type (systolic/diastolic/combined/right-sided), acuity (acute/chronic/acute-on-chronic), and etiology (hypertensive, cardiorenal, rheumatic, or idiopathic). Each dimension directly impacts HCC risk score, MS-DRG assignment, and quality metric attribution.
Cor pulmonale — right heart failure from pulmonary disease — is frequently under-documented and undercoded. The distinction between I27.81 (chronic cor pulmonale, HCC 223) and I50.81x (right HF codes) has both clinical and reimbursement significance. Always document the pulmonary etiology when right heart failure is present in a patient with significant lung disease.
Key Takeaways for CDI Teams
- Never leave “CHF” unspecified — always query for type and acuity
- When HTN and HF coexist: use I11.0 (or I13.x for CKD triad), not I10 + I50.x
- Acute-on-chronic HF (I50.x3 series) = HCC 221 (RAF ~0.331) — highest priority query
- End-stage HF (I50.84) requires explicit physician documentation
- FY2024 new codes I50.A1x/A2x: right HF with EF specification — query when echo available
- Cor pulmonale (I27.81) vs right HF (I50.81x) — document pulmonary etiology clearly
- HFimpEF: code the current EF state, not the historical nadir
- I51.81 (diastolic dysfunction) ≠ HFpEF — symptoms required for HF diagnosis
- BNP/NT-proBNP elevation alone does not establish HF — physician must document clinical HF diagnosis
Patient-Facing Education Points
- Daily weight monitoring: Weigh every morning after urinating; notify provider for >2–3 lb gain in 1–2 days (early sign of fluid accumulation)
- Sodium restriction: Limit sodium to <2,000–2,300 mg/day; avoid processed foods, canned soups, fast food
- Fluid restriction: Limit total fluid intake to 1.5–2 L/day if advised by physician
- Medication adherence: Never stop heart failure medications without physician guidance; some medications (beta-blockers) may worsen symptoms initially but improve long-term outcomes
- Activity: Participate in cardiac rehabilitation; gradually increase walking; avoid extreme heat/cold
- Warning signs requiring emergency care: Sudden severe shortness of breath, coughing pink/frothy sputum, inability to lie flat, rapid weight gain, extreme fatigue, syncope
- Cor pulmonale patients: Use supplemental oxygen as prescribed; smoking cessation is the single most effective intervention for COPD-related cor pulmonale
- Follow-up: Attend all scheduled cardiology and primary care appointments; TCM (CPT 99495/99496) support available within 7–14 days of hospital discharge reduces readmission risk
MS-DRG Quick Reference (FY2026)
| MS-DRG | Description | Geometric Mean LOS (approx.) | Notes |
|---|---|---|---|
| 291 | Heart Failure & Shock with MCC | ~4.8 days | Highest payment; requires MCC (e.g., acute renal failure, sepsis, ventilator) |
| 292 | Heart Failure & Shock with CC | ~3.4 days | Moderate complexity; CC required (e.g., atrial fibrillation, DM, COPD) |
| 293 | Heart Failure & Shock without CC/MCC | ~2.3 days | Lowest weight; query for CC/MCC to optimize DRG |
For additional coding resources, coding education, and CDI query tools, visit CCO Clinical Documentation Guides and the CMS FY2026 ICD-10-CM Official Guidelines.
About this Guide
This Clinical Documentation Guide is published by CCO Academy and is intended for credentialed coding, CDI, and clinical documentation professionals. Content is updated for FY2026 ICD-10-CM (effective October 1, 2025). All code assignments should be verified against the official ICD-10-CM Tabular List, AHA Coding Clinic, and applicable payer-specific policies. This guide does not constitute legal, medical, or compliance advice.
Last reviewed: April 2026 · Next scheduled review: October 2026 (FY2027 update)
Ready to turn this knowledge into a credential?
These Clinical Documentation Guides are a free companion to CCO’s paid training programs. Browse our full CCO Course, Blitz & Practice Exam Catalog — every core course, review blitz, practice exam, textbook, and free resource in one place — and find the perfect next step for your coding career.
